美银全球研究启动对Eikon Therapeutics的覆盖 给予买入评级及34美元目标价

美股速递
Mar 02

美银全球研究近日宣布,正式启动对生物科技公司Eikon Therapeutics(股票代码:EIKN)的研究覆盖,并首次给予"买入"评级。该机构同时设定了34美元的目标股价,显示出对该公司未来增长前景的积极预期。

此次覆盖启动标志着华尔街主要机构对Eikon Therapeutics在创新药物开发领域技术实力的认可。分析师在报告中指出,公司独特的平台技术和研发管线布局为其长期价值提升奠定了坚实基础。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10